CRISPR Therapeutics has advanced from a speculative biotech firm to a commercial-stage company with the FDA approval of its gene-editing therapy CASGEVY. This approval validates its CRISPR/Cas9 platform and supports its pipeline targeting large markets in cardiovascular, autoimmune, oncology, and diabetes diseases. Despite a strong cash position and valuable partnerships, most of its pipeline remains early stage, posing execution risks. The company is viewed as a speculative investment, with more attractive valuation potential below $52 per share.
CRISPR Therapeutics announced a leadership change with CFO Raju Prasad stepping down to pursue other opportunities. A.J. Silver, the company's Senior Vice President of Finance since 2025, will take over as CFO effective immediately. Silver brings ext...
Analysts show differing price targets for CRISPR Therapeutics, with UBS setting a modest $52 target and Citi projecting a bullish $88, driven by expected strong demand for Casgevy, an FDA-approved treatment for sickle cell disease. Despite positive a...
